Publications by authors named "J Gebhart"
There is no diagnostic test for primary immune thrombocytopenia (ITP). Certain microRNAs have shown to have diagnostic potential in ITP. We validated 12 microRNAs identified from two previous studies to find a diagnostic biomarker.
View Article and Find Full Text PDFBackground: Platelets are pivotal in maintaining vascular integrity, hemostasis, and immune modulation, with newly generated, immature platelets being the most responsive in fulfilling these tasks. Therefore, the immature platelet fraction provides insights into thrombopoiesis dynamics and clinical prognostication. However, it is currently unclear how immature platelet functions change in settings of acute thrombocytopenia.
View Article and Find Full Text PDFBackground: Treatment sequence in primary immune thrombocytopenia (ITP) is based on national and international recommendations, treatment availability, and physician expertise.
Aim: This article aimed to provide real-world data on treatment sequence and responses to first- and second-line treatments in newly diagnosed and relapsed adult ITP patients.
Methods: We analyzed a cohort of 46 adult ITP patients from the Vienna ITP Biobank, who started first-line therapy within 1 week before their first study visit between February 2016 and March 2023.
Article Synopsis
- Bleeding disorder of unknown cause (BDUC) is diagnosed after ruling out other causes, and this study analyzed data from 375 BDUC patients compared to 100 healthy controls.
- The findings revealed that BDUC patients had lower peak plasmin levels and clot density, indicating potential issues with clot structure, while still showing a higher potential for plasmin generation.
- A model including fibrinogen and plasmin generation parameters effectively distinguished BDUC patients from healthy controls, demonstrating the potential for predictive diagnostics in bleeding disorders.
Article Synopsis
- * In a study of 86 ITP patients and 78 healthy controls, findings showed that ITP patients had significantly slower clot lysis times and higher levels of plasminogen activator inhibitor-1 (PAI-1), while tissue plasminogen activator (tPA) levels were lower.
- * The results suggest that prolonged clot lysis time (CLT) and altered fibrinolysis mechanisms in ITP may contribute to thrombosis risk, with specifically higher tPA-PAI-1 complexes indicating potential